Hormone replacement therapy and cardiovascular disease: What went wrong and where do we go from here?

Hypertension

Volumn 44, Issue 6, 2004, Pages 789-795

  Dubey, Raghvendra K ^a,b   Imthurn, Bruno ^a,b   Zacharia, Lefteris C ^a   Jackson, Edwin K ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cardiovascular diseases; Estrogen; Hormones

Indexed keywords

2 HYDROXYESTRADIOL; CONJUGATED ESTROGEN; ESTRADIOL; ESTRIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE SULFATE; ETHINYLESTRADIOL; GESTAGEN; HYDROXYPROGESTERONE CAPROATE; MEDROXYPROGESTERONE; MESTRANOL; NORETHISTERONE ACETATE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CELL FUNCTION; CELL ISOLATION; CLINICAL TRIAL; ENDOTHELIUM CELL; GENETIC POLYMORPHISM; GENETICS; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; SIDE EFFECT; SMOOTH MUSCLE FIBER; SOCIOECONOMICS; VASCULAR SMOOTH MUSCLE;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ESTROGEN; RISK;

EID: 9644268035     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000145988.95551.28     Document Type: Short Survey

References (85)

1. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-613.
2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
3. Isles CG, Hole DJ, Hawthorne VM, Lever AF. Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: comparison with men. Lancet. 1992;339:702-706.
4. Tracy RE. Sex difference in coronary disease: two opposing views. J Chronic Dis. 1966;19:1245-1251.
5. Barrett-Connor E. Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. Circulation. 1997;95:252-264.
6. Maxwell SR. Women and heart disease. Basic Res Cardiol. 1998;93(Suppl 2):79-84.
7. Hodis HN, Mack WJ. Atherosclerosis imaging methods: assessing cardiovascular disease and evaluating the role of estrogen in the prevention of atherosclerosis. Am J Cardiol. 2002;89(suppl):19E-27E.
8. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA. 1991;265:1861-1867.
9. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med. 1976;85:447-452.
10. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med. 1987;316:1105-1110.
11. Hu FB, Grodstein F, Hennekens CH, Colditz GA, Johnson M, Manson JE, Rosner B, Stampfer MJ. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med. 1999;159:1061-1066.
12. Jacobsen BK, Nilssen S, Heuch I, Kvale G. Does age at natural menopause affect mortality from ischemic heart disease? J Clin Epidemiol. 1997;50:475-479.
13. van der Schouw YT, van der Graaf GY, Steyerberg EW, Eijkemans JC, Banga JD. Age at menopause as a risk factor for cardiovascular mortality. Lancet. 1996;347:714-718.
14. Joakimsen O, Bonaa KH, Stensland-Bugge E, Jacobsen BK. Population-based study of age at menopause and ultrasound assessed carotid atherosclerosis: The Tromso Study. J Clin Epidemiol. 2000;53:525-530.
15. Bush TL, Cowan LD, Barrett-Connor E, Criqui MH, Karon JM, Wallace RB, Tyroler HA, Rifkind BM. Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics Program Follow-Up Study. JAMA. 1983;249:903-906.
16. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation. 1987;75:1102-1109.
17. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
18. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health. 1998;19:55-72.
19. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933-941.
20. Sudhir K, Chou TM, Chatterjee Kanu, Smith EP, Williams TC, Kane JP, Malloy MJ, Korach KS, Rubanyi GM. Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation. 1997;96:3774-3777.
21. Shearman AM, Cupples LA, Demissie S, Peter I, Schmid CH, Karas RH, Mendelsohn, ME, Housman DE, Levy D. Association between estrogen receptor α gene variation and cardiovascular disease. JAMA. 2003;290:2263-2270.
22. Lehtimaki T, Kunnas TA, Mattila KM, Perola M, Penttila A, Koivula T, Karhunen PJ. Coronary artery wall atherosclerosis in relation to the estrogen receptor 1 gene polymorphism: an autopsy study. J Mol Med. 2002;80:176-180.
23. Herrington DM, Howard TD, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Brosnihan KB, Meyers DA, Bleecker ER. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med. 2002;346:967-974.
24. Lu H, Higashikata T, Inazu A, Nohara A, Yu W, Shimizu M, Mabuchi H. Association of estrogen receptor-alpha gene polymorphisms with coronary artery disease in patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2002;22:817-823.
25. Ferrero V, Ribichini F, Matullo G, Guarrera S, Carturan S, Vado A, Vassanelli C, Piazza A, Uslenghi E, Wijns W. Estrogen receptor-α polymorphisms and angiographic outcome after coronary artery stenting. Arterioscler Thromb Vasc Biol. 2003;23:2223-2228.
26. Ogawa S, Emi M, Shiraki M, Hosoi T, Ouchi Y, Inoue S. Association of estrogen receptor beta (ESR2) gene polymorphism with blood pressure. J Hum Genet. 2000;45:327-330.
27. Dubey RK, Jackson EK. Estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms. Am J Physiol Renal Physiol. 2001;280:F365-F388.
28. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:49-57.
29. Wenger NK, Knatterud GL, Canner PL. Early risks of hormone therapy in patients with coronary heart disease. JAMA. 2000;284:41-43.
30. Byington RP, Furberg CD, Herrington DM, Herd JA, Hunninghake D, Lowery M, Riley W, Craven T, Chaput L, Ireland CC, Applegate WB. Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy. Arterioscler Thromb Vasc Biol. 2002;22:1692-1697.
31. Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schofiel PM. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. Br J Obstet Gynecol. 2002;109:1056-1062.
32. Cherry N, Gilmour K, Hannaford P, Heagerty A, Khan MA, Kitchener H, McNamee R, Elstein M, Kay C, Seif M, Buckley H. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet. 2002;360:2001-2008.
33. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343:522-529.
34. Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ, Ouyang P, Thompson P, Tardif JC, Higginson L, Bittner V, Steffes M, Gordon DJ, Proschan M, Younes N, Verter JI. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002;288:2432-2440.
35. Angerer P, Stork S, Kothny W, Schmitt P, von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol. 2001;21:262-268.
36. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res. 2002;53:605-619.
37. Adams MR, Kaplan JR, Manuck SB, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis. 1990;10:1051-1057.
38. Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab. 1998;83:721-726.
39. Clarkson TB, Anthony MS, Wagner JD. A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. J Clin Endocrinol Metab. 2001;86:5396-5404.
40. Clarkson TB, Anthony MS, Morgan TM. Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J Clin Endocrinol Metab. 2001;86:41-47.
41. Williams JK, Anthony MS, Honore EK, Herrington DM, Morgan TM, Register TC, Clarkson TB. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol. 1995;15:827-836.
42. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ. 1997;315:149-153.
43. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273:199-208.
44. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu CR, Liu CH, Azen SP. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;135:939-953.
45. Espeland MA, Applegate W, Furberg CD, Lefkowitz D, Rice L, Hunninghake D. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. Asymptomatic Carotid Atherosclerosis Prevention Study. Am J Epidemeol. 1995;142:1011-1019.
46. Hodis HN, Mack WJ, Azen SP, Lobo RA, Shoupe D, Mahrer PR, Faxon DP, Cashin-Hemphill L, Sanmarco ME, French WJ, Shook TL, Gaarder TD, Mehra AO, Rabbani R, Sevanian A, Shil AB, Torres M, Vogelbach KH, Selzer RH. Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med. 2003;349:535-545.
47. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S, Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The womens health initiative randomized controlled trial. JAMA. 2004;291:1701-1712.
48. Blankenhorn DH, Hodis HN. Arterial Imaging and atherosclerosis reversal. Arterioscler Thromb Vasc Biol. 1994;14:177-192.
49. Homma S, Hirose N, Ishida H, Ishii T, Araki G. Carotid plaque and intima-media thickness assessed by B-mode ultrasonography in subjects ranging from young adults to centenarians. Stroke. 2001;32:830-835.
50. Mori T, Durand J, Chen Y-F, Thompson A, Bakir S, Oparil S. Effects of short-term estrogen treatment on the neointimal response to balloon injury of rat carotid artery. Am J Cardiol. 2000;85:1276-1279.
51. Finking G, Krauss N, Römer S, Eckert S, Lenz C, Kamenz J, Menke A, Brehme U, Hombach V, Hanke H. 17β-estradiol, gender independently, reduces atheroma development but not neointimal proliferation after balloon injury in the rabbit aorta. Atherosclerosis. 2001;154:39-49.
52. Strong JP, Malcom GT, McMahan CA, Tracy RE, Newman WP 3rd, Herderick EE, Cornhill JF. Prevalance and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA. 1999;281:727-735.
53. McGill HC Jr, Stern MP. Sex and atherosclerosis. Atheroscler Rev. 1979;4:157-242.
54. Tejada C, Strong JP, Montenegro MR, Restrepo C, Solberg LA. Distribution of coronary and aortic atherosclerosis by geographic location, race, and sex. Lab Invest. 1968;18:509-526.
55. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453-461.
56. Iribarren C, Luepker RV, McGovern prostaglandin (PG), Arnett DK, Blackburn H. Twelve-year trends in cardiovascular disease risk factors in the Minnesota Heart Survey. Are socioeconomic differences widening? Arch Intern Med. 1997;157:873-881.
57. Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med. 2002;137:273-284.
58. Grodstein F, Stamfer MJ, Falkeborn M, Naessen T, Persson I. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women. Epidemeology. 1999;10:476-480.
59. Dubey RK, Gillespie DG, Zacharia LC, Imthurn B, Jackson EK, Keller PJ. Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and MAP kinase activity. Arterioscler Thromb Vasc Biol. 2000;20:964-972.
60. Geary RL, Adams MR, Benjamin ME, Williams JK. Conjugated equine estrogens inhibit progression of atherosclerosis but have no effect on intimal hyperplasia or arterial remodeling induced by balloon catheter injury in monkeys. J Am Coll Cardiol. 1998;31:1158-1164.
61. Dubey RK, Gillespie DG, Zacharia LC, Barchiesi LC. Imthurn B, Jackson EK. CYP450- and COMT-Derived estradiol metabolites inhibit activity of human coronary artery SMCs. Hypertension. 2003;41:807-813.
62. Dubey RK, Gillespie DG, Zacharia LC, Rosselli M, Imthurn B, Jackson EK. Methoxyestradiols mediate the antimitogenic effects of locally applied estradiol on cardiac fibroblast growth. Hypertension. 2002;39:412-417.
63. Dubey RK, Gillespie DG, Keller PJ, Imthurn B, Zacharia LC, Jackson EK. Role of methoxyestradiols in the growth inhibitory effects of estradiol on human glomerular mesangial cells. Hypertension. 2002;39:418-424.
64. Zacharia LC, Gogos JA, Karayiorgou M, Jackson EK, Gillespie DG, Barchiesi F, Dubey RK. Methoxyestradiols mediate the antimitogenic effects of 17beta-estradiol: direct evidence from catechol-O-methyltransferase-knockout mice. Circulation. 2003;108:2974-2978.
65. Tofovic S, Dubey RK, Jackson EK. 2-Hydroxyestradiol attenuates the development of obesity, the metabolic syndrome, and vascular and renal dysfunction in obese ZSF1 rats. J Pharmacol Expt Therap. 2001;299:973-977.
66. Iafrati MD, Karas RH, Aronovitz M, Kim S, Sullivan TR Jr., Lubahn DB, O'Donnell TF Jr., Korach KS, Mendelsohn ME. Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nature Med. 1997;3:545-548.
67. Karas RH, Hodgin JB, Kwoun M, Krege JH, Aronovitz M, Mackey W, Gustafsson JA, Korach KS, Smithies O, Mendelsohn ME. Estrogen inhibits the vascular injury response in estrogen receptor-deficient female mice. Proc Natl Acad Sci USA. 1999;96:15133-15136.
68. Oparil S, Levine RL, Chen SJ, Durand J, Chen YF. Sexually dimorphic response of the balloon-injured rat carotid artery to hormone treatment. Circulation. 1997;95:1301-1307.
69. Levine RL, Chen SJ, Durand J, Chen YF, Oparil S. Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. Circulation. 1996;94:2221-2227.
70. Dubey RK, Zacharia LC, Barchiesi F, Jackson EK, Fingerle J. Inhibitory effects of androgens on estradiol metabolsim may contribute to the decreased protective effects of estradiol on neointima formation on male rats. Hypertension. 2001;38:480 (abstract).
71. Sudhir K, Esler MD, Jennings GL, Komesaroff PA. Estrogen supplementation decreases norepinephrine-induced vasoconstriction and total body norepinephrine spillover in perimenopausal women. Hypertension. 1997;30:1538-1543.
72. Vongpatanasin W, Tuncel M, Mansour Y, Arbique D, Victor RG. Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women. Circulation. 2001;103:2903-2908.
73. Del Rio G, Velardo A, Menozzi R, Zizzo G, Tavernari V, Venneri MG, Marrama P, Petraglia F. Acute estradiol and progesterone administration reduced cardiovascular and catecholamine responses to mental stress in menopausal women. Neuroendocrinology. 1998;67:269-274.
74. Ng AV, Callister R, Johnson DG, Seals DR. Age and gender influence muscle sympathetic nerve activity at rest in healthy humans. Hypertension. 1993;21:498-503.
75. Dubey RK, Jackson EK, Gillespie DG, Zacharia LC, Imthurn B. Catecholamines block the antimitogenic effects of estradiol on human coronary artery smooth muscle cells. J Clin Endocrinol Metab. 2004;89:(in press).
76. Williams JK, Adams MR, Herrington DM, Clarkson TB. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol. 1992;20:452-457.
77. Arrowood JA, Fisher MR, Allen KA, Bierne R, Thakur A, Makhoul RG, Nixon RV. Hormone replacement preserves endothelial function in post-menopausal women with only risk factors for coronary disease. Circulation Suppl 2000;102:108.
78. Koh KK, Jin DK, Yang SH, Lee SK, Hwang HY, Kang MH, Kim W, Kim DS, Choi IS, Shin EK. Vascular effects of synthetic or natural progestogen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation. 2001;103:1961-1966.
79. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effects of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation. 2001;104:1773-1778.
80. Harboo J, Leth-Espensen P, Stender S, Christiansen C. Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovarectomized cholesterol-fed rabbits. J Clin Invest. 1991;87:1274-1279.
81. Alexandersen P, Haarbo J, Sandholdt I, Shalmi M, Lawaetz H, Christiansen C. Norethindrone acetate enhances the antiatherogenic effect of 17β-estradiol: a secondary prevention study of aortic atherosclerosis in ovarectomized cholesterol fed rabbits. Arterioscler Thromb Vasc Biol. 1998;18:902-907.
82. Brehme U, Bruck B, Gugel N, Wehrmann M, Hanke S, Finking G, Schmahl FW, Hanke H. Aortic plaque size and endometrial response in cholesterol fed rabbits treated with estrogen plus continuous or sequential progestin. Arterioscler Thromb Vasc Biol. 1999;19:1930-1937.
83. Antony MS. Effects of hormone replacement therapy on atherosclerosis (thesis). Winston-Salem, NC: Wake Forest University; 2001.
84. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab. 2003;88:2470-2478.
85. Decensi A, Omodei U, Robertson C, Bonanni B, Guerrieri-Gonzaga A, Ramazzotto F, Johansson H, Mora S, Sandri MT, Cazzaniga M, Franchi M, Pecorelli S. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation. 2002;106:1224-1228.